BioSpace News Archive

Masimo announced that Germans Trias i Pujol, a pioneering hospital serving more than 800,000 people in north Barcelona, Spain, is launching a breakthrough telehealth and remote patient management initiative using Masimo technology.

PhoreMost Ltd., has triggered a second milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim.

NeoImmuneTech, Inc., a T cell-focused therapeutics company, announced promising interim results of its major clinical trial NIT-110 of NT-I7, at the 2024 American Society of Clinical Oncology global meeting held in Chicago, from May 31 to June 4.

MediciNova, Inc. announced that MediciNova’s collaborator, Gilbert Youssef, M.D. at Harvard Medical School, Attending Physician, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, presented new data and results of a Phase 1b/2a Clinical Trial of MN-166 in Glioblastoma at the American Society of Clinical Oncology Annual meeting 2024 held May 31- June 4th in Chicago, IL.

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced updated clinical results from the ongoing investigator-sponsored Phase 2 trial of darovasertib, a first-in-class oral, small molecular inhibitor of protein kinase C, as neoadjuvant/adjuvant treatment in uveal melanoma and clinical update for Phase 2 company-sponsored neoadjuvant UM study.

BD, a leading global medical technology company, and Edwards Lifesciences, announced a definitive agreement under which BD will acquire Edwards’ Critical Care product group, a global leader in advanced monitoring solutions, for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD’s portfolio of smart connected care solutions.

KalVista Pharmaceuticals, Inc., announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the European Academy of Allergy and Clinical Immunology Congress 2024 that took place in Valencia, Spain.

Bio-Path Holdings, Inc. presented interim results from the Company’s Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia in an oral presentation at the American Society of Clinical Oncology Annual Meeting, on June 1, 2024 in Chicago, IL.

Kraig Biocraft Laboratories, Inc., announces that Kraig Labs is now in production with its BAM-1 recombinant spider silk hybrids.

Beyond Cancer, Ltd. announced encouraging first-in-class clinical data demonstrating evidence of immune system activation via biomarker response in a heavily pretreated population in the ongoing Phase 1a trial.